Study That Will Evaluate the Brazilian Population With COPD.
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAstraZeneca
About this trial
Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.
Eligibility criteria
Qualifiers
Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT >=10); or
GOLD E (>=2 moderate or 1 severe exacerbation - hospitalization); or
GOLD 3 and 4 (FEV1 <50%).
Disqualifiers
Advanced fibrosing interstitial lung disease (extent >=50%); and/or
High-risk pulmonary hypertension (on triple therapy); and/or
Active cancer - on systemic therapy
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov